STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] PALATIN TECHNOLOGIES INC Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Palatin Technologies reported that underwriters exercised their over-allotment option tied to its recent public offering. The underwriters purchased 280,615 common shares at $6.50, plus pre-funded warrants for 84,000 shares at $6.50, and the company issued accompanying Series J warrants to buy up to 364,615 shares at $6.50 and Series K warrants to buy up to 364,615 shares at $8.125. This added approximately $2.37 million in gross proceeds, before fees and expenses.

After giving effect to the over-allotment exercise, total gross proceeds from the offering rose to approximately $18.2 million. Palatin also filed a legal opinion covering the securities and noted a related press release.

Positive
  • None.
Negative
  • None.

Insights

Over-allotment exercised, modest additional cash; neutral impact.

Palatin Technologies confirmed the underwriters’ over-allotment exercise, adding gross proceeds of $2.37 million and lifting total gross proceeds to $18.2 million. Instruments include common shares, pre-funded warrants at $6.50, and Series J/K warrants with exercise prices of $6.50 and $8.125, respectively.

This is a standard follow-on mechanism and does not change strategy by itself. Any future dilution depends on if and when warrant holders exercise. Proceeds are gross and will be reduced by fees and expenses.

The filing mentions completion on November 12, 2025. Subsequent disclosures may detail net proceeds and any use of funds, as applicable.

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 12, 2025

 

PALATIN TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-15543

 

95-4078884

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

103 Carnegie Center Drive, Suite 300, Princeton, NJ

 

08512

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (609) 495-2200

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading symbol

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

PTN

 

NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 8.01 Other Events.

  

On November 12, 2025, Palatin Technologies, Inc., a Delaware corporation (the “Company”), closed on the exercise of the over-allotment option by A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd. (the “Underwriters”), in connection with the Company’s firm commitment public offering (the “Offering”), pursuant to which the Underwriters purchased and exercised, as applicable, an aggregate of (i) 280,615 shares (the “Shares”) of common stock, par value $0.01 per share, of the Company (the “Common Stock”) at an offering price per share of $6.50, (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 84,000 shares of Common Stock at an offering price per share of $6.50 (the “Pre-Funded Warrant Shares”), (iii) accompanying Series J common stock purchase warrants (the “Series J Warrants”) to purchase up to 364,615 shares of Common Stock with an exercise price per share of $6.50 (the “Series J Warrant Shares”), and (iv) accompanying Series K common stock purchase warrants (the “Series K Warrants”) to purchase up to 364,615 shares with an exercise price per share of $8.125 (the “Series K Warrant Shares”), resulting in additional gross proceeds of approximately $2.37 million, before deducting underwriting fees and other estimated offering expenses payable by the Company. After giving effect to the exercise of the over-allotment option, the gross proceeds from the Offering increased to approximately $18.2 million. The Shares, Pre-Funded Warrants, Pre- Funded Warrant Shares, Series J Warrants, Series J Warrant Shares, Series K Warrants, and Series K Warrant Shares are referred to collectively as the “Securities.”

 

A copy of the opinion of Thompson Hine LLP relating to the legality of the Securities offered by the Company upon exercise of the Underwriters’ over-allotment option is attached as Exhibit 5.1 hereto.

 

The Company issued a press release on November 12, 2025 announcing the sale of the Securities. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

  

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.

 

Description

5.1

 

Opinion of Thompson Hine LLP, dated November 12, 2025.

99.1

 

Press Release, dated November 12, 2025.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 12, 2025

 

PALATIN TECHNOLOGIES, INC.

 

 

 

 

 

 

 

/s/ Stephen T. Wills

 

 

 

Stephen T. Wills, CPA, MST

 

 

 

Executive Vice President, Chief Financial

Officer and Chief Operating Officer

 

 

 

3

 

FAQ

What did Palatin Technologies (PTNT) announce regarding its offering?

Underwriters exercised their over-allotment option, adding approximately $2.37 million in gross proceeds and increasing total gross proceeds to about $18.2 million.

How many additional securities were involved in PTNT’s over-allotment exercise?

The underwriters purchased 280,615 shares and pre-funded warrants for 84,000 shares, with accompanying Series J and Series K warrants for up to 364,615 shares each.

What are the prices tied to the newly issued instruments for PTNT?

Shares and pre-funded warrants were priced at $6.50 per share; Series J warrants have a $6.50 exercise price, and Series K warrants have an $8.125 exercise price.

What is the total gross proceeds from PTNT’s offering after the over-allotment?

Total gross proceeds increased to approximately $18.2 million.

Did PTNT include legal documentation with this update?

Yes. An opinion of Thompson Hine LLP covering the securities was filed as Exhibit 5.1, and a related press release as Exhibit 99.1.

Which firms acted as underwriters for PTNT’s offering?

The underwriters were A.G.P./Alliance Global Partners and Laidlaw & Company (UK) Ltd.
Pathnet Inc

OTC:PTNT

PTNT Rankings

PTNT Latest News

PTNT Latest SEC Filings

PTNT Stock Data

7.99M
45.96M
1.85%
8.18%
6.76%
Biotechnology
Healthcare
Link
United States
Cranbury